Thoracic SMARCA4-deficient undifferentiated tumor-a case of an aggressive neoplasm-case report.

Mediastinum (Hong Kong, China) Pub Date : 2021-12-25 eCollection Date: 2021-01-01 DOI:10.21037/med-20-15
Anja C Roden
{"title":"Thoracic SMARCA4-deficient undifferentiated tumor-a case of an aggressive neoplasm-case report.","authors":"Anja C Roden","doi":"10.21037/med-20-15","DOIUrl":null,"url":null,"abstract":"<p><p>Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms that most commonly occur in the mediastinum of male smokers. These tumors are characterized by an inactivating mutation of <i>SMARCA4</i> resulting in loss of expression of brahma-related gene 1 (BRG1). These tumors can have a variable immunophenotype but in general have no or only focal keratin expression and characteristically lack expression of BRG1. Most patients have metastatic disease at time of presentation. Usually SMARCA4-UT progress or recur and the median survival of these patients is only approximately half a year. Preclinical and clinical trials using enhancer of zeste homolog (EZH2) inhibitors are underway to potentially treat this neoplasm. In addition, rare cases of successful treatment with anti-PD-1 inhibitors are described. Here, the case of a 66-year-old male smoker who presents with mediastinal and left suprahilar masses and widespread metastatic disease is reported. A biopsy reveals extensive necrosis and clusters and small sheets of neoplastic epithelioid cells with some exhibiting rhabdoid cytology. The tumor cells lack staining with various keratins and markers of lymphoid, melanocytic, myogenic, or vascular differentiation. Focal expression of CD30 is noted. BRG1 expression is lost in the tumor cells while INI-1 expression is preserved. This tumor is diagnosed as SMARCA4-UT.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/95/med-05-39.PMC8794332.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediastinum (Hong Kong, China)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/med-20-15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms that most commonly occur in the mediastinum of male smokers. These tumors are characterized by an inactivating mutation of SMARCA4 resulting in loss of expression of brahma-related gene 1 (BRG1). These tumors can have a variable immunophenotype but in general have no or only focal keratin expression and characteristically lack expression of BRG1. Most patients have metastatic disease at time of presentation. Usually SMARCA4-UT progress or recur and the median survival of these patients is only approximately half a year. Preclinical and clinical trials using enhancer of zeste homolog (EZH2) inhibitors are underway to potentially treat this neoplasm. In addition, rare cases of successful treatment with anti-PD-1 inhibitors are described. Here, the case of a 66-year-old male smoker who presents with mediastinal and left suprahilar masses and widespread metastatic disease is reported. A biopsy reveals extensive necrosis and clusters and small sheets of neoplastic epithelioid cells with some exhibiting rhabdoid cytology. The tumor cells lack staining with various keratins and markers of lymphoid, melanocytic, myogenic, or vascular differentiation. Focal expression of CD30 is noted. BRG1 expression is lost in the tumor cells while INI-1 expression is preserved. This tumor is diagnosed as SMARCA4-UT.

Abstract Image

胸部smarca4缺陷未分化肿瘤-侵袭性肿瘤1例报告。
胸部smarca4缺陷未分化肿瘤(SMARCA4-UT)是侵袭性肿瘤,最常见于男性吸烟者的纵隔。这些肿瘤的特征是SMARCA4失活突变导致brahma相关基因1 (BRG1)的表达缺失。这些肿瘤可以具有可变的免疫表型,但通常没有或只有局灶性角蛋白表达,并且典型地缺乏BRG1的表达。大多数患者在发病时已经有转移性疾病。通常SMARCA4-UT进展或复发,这些患者的中位生存期仅为大约半年。使用zeste同系物增强剂(EZH2)抑制剂治疗这种肿瘤的临床前和临床试验正在进行中。此外,用抗pd -1抑制剂成功治疗的罕见病例也被描述。本文报告一位66岁男性吸烟者,表现为纵隔及左侧门上肿物及广泛转移性疾病。活检显示广泛坏死,肿瘤上皮样细胞呈簇状和小片状,其中一些呈横纹肌样细胞学。肿瘤细胞缺乏各种角蛋白和淋巴细胞、黑素细胞、肌源性或血管分化标记物的染色。可见CD30的局灶性表达。BRG1在肿瘤细胞中表达缺失,而ni -1表达保留。该肿瘤诊断为SMARCA4-UT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信